Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 144

Similar articles for PubMed (Select 22903535)

1.

PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy.

Chen YZ, Xue JY, Chen CM, Yang BL, Xu QH, Wu F, Liu F, Ye X, Meng X, Liu GY, Shen ZZ, Shao ZM, Wu J.

Cancer Chemother Pharmacol. 2012 Nov;70(5):637-44. doi: 10.1007/s00280-012-1949-0. Epub 2012 Aug 19.

PMID:
22903535
2.

Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.

Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Ann Oncol. 2010 May;21(5):961-7. doi: 10.1093/annonc/mdq041. Epub 2010 Mar 8.

3.

Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.

Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K, Nakayama T, Kim SJ, Tamaki Y, Noguchi S.

Eur J Cancer. 2011 Aug;47(12):1779-88. doi: 10.1016/j.ejca.2011.06.017. Epub 2011 Jul 7.

PMID:
21741827
4.

Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients.

Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, Katsumata N, Kang YK, Nishio K, Fujiwara Y.

Breast Cancer Res Treat. 2006 Sep;99(1):9-17. Epub 2006 Jun 5.

PMID:
16752223
5.

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2006 Sep 10;24(26):4236-44. Epub 2006 Aug 8.

6.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S.

J Clin Oncol. 2005 Oct 10;23(29):7265-77. Epub 2005 Sep 6.

7.

Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.

Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K, Parker JS, Swain SM, Hunter K, Zujewski JA.

Breast Cancer Res Treat. 2010 Feb;119(3):685-99. doi: 10.1007/s10549-009-0651-3.

PMID:
20012355
8.

Evaluation of biological pathways involved in chemotherapy response in breast cancer.

Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L.

Breast Cancer Res. 2008;10(2):R37. doi: 10.1186/bcr2088. Epub 2008 Apr 29.

9.
10.

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.

Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L.

Breast Cancer Res. 2007;9(6):R87.

11.

HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.

Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.

Breast Cancer Res Treat. 2008 Mar;108(2):183-90. Epub 2007 Apr 28.

PMID:
17468948
12.

Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.

Sarid D, Ron IG, Sperber F, Stadler Y, Kahan P, Kovner F, Ben-Yosef R, Marmor S, Grinberg Y, Maimon N, Weinstein J, Yaal-Hahoshen N.

Clin Drug Investig. 2006;26(12):691-701.

PMID:
17274676
13.

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2004 Jun 15;22(12):2284-93. Epub 2004 May 10.

14.

Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.

Barros Filho MC, Katayama ML, Brentani H, Abreu AP, Barbosa EM, Oliveira CT, Góes JC, Brentani MM, Folgueira MA.

Braz J Med Biol Res. 2010 Dec;43(12):1225-31. Epub 2010 Nov 26.

15.

Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.

Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, Bobos M, Kalofonos HP, Petraki K, Pavlakis K, Bafaloukos D, Fountzilas G.

Clin Breast Cancer. 2010 Jun;10(3):230-7. doi: 10.3816/CBC.2010.n.031.

PMID:
20497922
16.

Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer.

Maher SG, Gillham CM, Duggan SP, Smyth PC, Miller N, Muldoon C, O'Byrne KJ, Sheils OM, Hollywood D, Reynolds JV.

Ann Surg. 2009 Nov;250(5):729-37. doi: 10.1097/SLA.0b013e3181bce7e1.

PMID:
19801928
17.

Semaphorin-plexin signalling genes associated with human breast tumourigenesis.

Gabrovska PN, Smith RA, Tiang T, Weinstein SR, Haupt LM, Griffiths LR.

Gene. 2011 Dec 10;489(2):63-9. doi: 10.1016/j.gene.2011.08.024. Epub 2011 Sep 2.

PMID:
21925246
18.

Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial.

Shen K, Qi Y, Song N, Tian C, Rice SD, Gabrin MJ, Brower SL, Symmans WF, O'Shaughnessy JA, Holmes FA, Asmar L, Pusztai L.

BMC Med Genomics. 2012 Nov 16;5:51. doi: 10.1186/1755-8794-5-51.

19.

Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy.

Koike Folgueira MA, Brentani H, Carraro DM, De Camargo Barros Filho M, Hirata Katayama ML, Santana de Abreu AP, Mantovani Barbosa E, De Oliveira CT, Patrão DF, Mota LD, Netto MM, Caldeira JR, Brentani MM.

Oncol Rep. 2009 Oct;22(4):805-13.

PMID:
19724859
20.

Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study.

Ahmed S, Birnbaum AE, Safran HP, Dipetrillo TA, Aswad BI, Ready NE, Ng T.

J Thorac Oncol. 2011 Aug;6(8):1432-4. doi: 10.1097/JTO.0b013e3182209043.

PMID:
21847062
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk